Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study

Benefits from the first year of GnRHa therapy in boys with idiopathic central precocious puberty when initiating treatment after age 9 years: findings from a real-world retrospective study

Abstract Background GnRHa treatment was established for improving final adult height (FAH) in children presenting with Idiopathic central precocious puberty (ICPP) up to age 8, while several controversies remained for older age groups. The primary objective was to evaluate whether boys diagnosed wit...

Full description

Bibliographic Details
Main Authors: Ming-ming Ni, Shu-ting Yang, Wen-wen Wu, Shan-shan Wang, Man Li, Qing-qing Liu, Xing Ji
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Endocrine Disorders
Subjects:
Idiopathic central precious puberty
Gonadotrophin-releasing hormone analog
Final adult height
Predicted adult height
Bone age
Online Access:https://doi.org/10.1186/s12902-022-01207-z

Internet

https://doi.org/10.1186/s12902-022-01207-z

Similar Items